The National Times - Stocks diverge as traders weigh US inflation, Trump pharma tariff

Stocks diverge as traders weigh US inflation, Trump pharma tariff


Stocks diverge as traders weigh US inflation, Trump pharma tariff
Stocks diverge as traders weigh US inflation, Trump pharma tariff / Photo: © GETTY IMAGES NORTH AMERICA/AFP

European stocks rose Friday after losses in Asia, as traders awaited key US inflation data and digested President Donald Trump's fresh tariffs set to impact pharmaceuticals and other sectors.

Change text size:

The dollar dropped ahead of the Federal Reserve's preferred gauge of inflation -- the personal consumption expenditure (PCE) index -- with traders keenly seeking clues on how much further the US central bank could cut interest rates this year.

Official data Thursday showing faster-than-expected US economic growth in the second quarter dampened slightly expectations of a Fed cut next month, which would follow on from its September reduction, the first this year.

"On the surface, strong GDP should be good news but the problem is, such strong growth doesn't support further Federal Reserve rate cuts, and it could even boost inflation expectations on top of potential tariff-led pressures," noted Swissquote Bank senior analyst Ipek Ozkardeskaya.

Trump's announcement Thursday of steep new tariffs on medicines and other goods drew pushback from some allies, with the European Union claiming immunity for its pharmaceutical industry under a bilateral trade deal.

A 100-percent levy on pharmaceuticals, starting October 1, is the harshest trade policy by the president since April's shock unveiling of "reciprocal" tariffs on virtually every US trading partner across the globe.

In reaction, share prices of Asian pharma firms largely fared worse compared with European peers.

Shanghai Fosun shed around six percent and South Korea's Daewoong was off more than three percent. Japan's Daiichi Sankyo and Astellas Pharma were also well in the red.

Sydney-listed CSL shed nearly two percent, while Sun Pharmaceutical Industries was a major loser in India.

Key industry player India "could be spared" from the levies for now, however, according to MUFG bank analyst Michael Wan.

"It is still unclear how branded or patented pharmaceutical products will be defined, but our working assumption is that this will not incorporate generic drugs and pharmaceuticals shipped by the likes of India to the US," he wrote in a client note.

Shares prices of British pharma giants GSK and AstraZeneca were both rising in London midday deals, with both companies having recently announced major investment plans in the United States.

- Key figures at around 1045 GMT -

London - FTSE 100: UP 0.3 percent at 9,243.75 points

Paris - CAC 40: UP 0.4 percent at 7,821.61

Frankfurt - DAX: UP 0.3 percent at 23,596.41

Tokyo - Nikkei 225: DOWN 0.9 percent at 45,354.99 (close)

Hong Kong - Hang Seng Index: DOWN 1.4 percent at 26,128.20 (close)

Shanghai - Composite: DOWN 0.7 percent at 3,828.11 (close)

New York - Dow: DOWN 0.4 percent at 45,947.32 (close)

Euro/dollar: UP at $1.1669 from $1.1658 on Thursday

Pound/dollar: UP at $1.3347 from $1.3335

Dollar/yen: UP at 149.89 yen from 149.81 yen

Euro/pound: DOWN at 87.41 pence from 87.42 pence

Brent North Sea Crude: DOWN 0.1 percent at $68.52 per barrel

West Texas Intermediate: DOWN 0.1 percent at $64.90 per barrel

burs-bcp/ajb/lth

Q.Marshall--TNT

Featured

AI Risks to Enter 60–80% of Liability and Cyber Insurance Underwriting by 2028, ScienceSoft Predicts

ScienceSoft has released proprietary research on how midsize US insurers will address artificial intelligence (AI) risks in coverage and underwriting through 2028. Drawing on insurance market data, perspectives from industry experts, and ScienceSoft’s experience working with insurance organizations, the research examines whether growing AI-related losses will lead to a new class of AI-specific insurance.

ECB lifts borrowing costs amid energy shock, opens door for more hikes

The European Central Bank raised interest rates Thursday for the second time this year as renewed Middle East fighting fans fears of higher inflation, and opened the door for further hikes.

Tribal Launches Campfire, Letting Business and Technical Teams Build on Salesforce Together

Tribal’s Campfire is a shared canvas that lets enterprises build and change their own Salesforce org at the speed of business, with security, permissions and dependencies intact 

Global Tokenized Real Estate Market to Hit up to $3 Trillion by 2030, ScienceSoft Predicts

ScienceSoft has released new proprietary research on the role of tokenization in the real estate investment landscape. Drawing on market statistics, firsthand perspectives from industry experts, and ScienceSoft’s experience delivering technology projects in the niche, the report examines whether tokenized real estate will evolve into a mainstream investment vehicle.

Change text size: